(Q41148049)

27 September 2017

1 reference

title

Role of interleukin-2 in human hematological malignancies (English)

1 reference

27 September 2017

A Toren

1

1 reference

27 September 2017

A Ackerstein

series ordinal

2

1 reference

27 September 2017

S Slavin

series ordinal

3

1 reference

27 September 2017

A Nagler

series ordinal

4

1 reference

27 September 2017

publication date

1 September 1995

1 reference

27 September 2017

1 reference

27 September 2017

volume

12

1 reference

27 September 2017

issue

3

1 reference

27 September 2017

page(s)

177-186

1 reference

Treatment of chronic myelogenous leukemia with recombinant human interleukin-2 and interferon-alpha 2a.

27 September 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF01571195

Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF01571195

Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF01571195

Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse

21 January 2018

1 reference

12 December 2020

Induction of NK cell activity against fresh human leukemia in culture with interleukin 2

1 reference

12 December 2020

Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia

1 reference

12 December 2020

Amplification of the graft-versus-leukemia effect in man by interleukin-2

1 reference

12 December 2020

Interleukin 2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia--a phase I study

1 reference

12 December 2020

Kettering Award Lecture. The role of marrow transplantation in the eradication of malignant disease

1 reference

12 December 2020

The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes

1 reference

12 December 2020

Interleukin-2 in cancer therapy

1 reference

12 December 2020

The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma

1 reference

12 December 2020

Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia

1 reference

12 December 2020

Defective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin 2

1 reference

12 December 2020

Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens

1 reference

12 December 2020

Interleukin 2 does not promote the in vitro and in vivo proliferation and growth of human acute leukaemia cells of myeloid and lymphoid origin

1 reference

12 December 2020

Breast cancer gene therapy: transgenic immunotherapy

1 reference

12 December 2020

Enhancement of GVL effect with rhIL-2 following BMT in a murine model for acute myeloid leukemia in SJL/J mice

1 reference

12 December 2020

Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation

1 reference

12 December 2020

Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders

1 reference

12 December 2020

Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data

1 reference

12 December 2020

Eosinophils activation in post-autologous bone marrow transplanted patients treated with subcutaneous interleukin-2 and interferon-alpha 2A immunotherapy

1 reference

12 December 2020

T-cell depletion in allogeneic bone marrow transplantation: progress and problems

1 reference

12 December 2020

High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults

1 reference

12 December 2020

How does bone-marrow transplantation cure leukaemia?

1 reference

12 December 2020

Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation

1 reference

12 December 2020

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

1 reference

12 December 2020

Cytotoxic effects of tumour necrosis factor and gamma-interferon on acute myeloid leukaemia blasts

1 reference

12 December 2020

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

1 reference

12 December 2020

Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation

1 reference

12 December 2020

Cellular interactions in marrow-grafted patients. I. Impairment of cell-mediated lympholysis associated with graft-vs-host disease and the effect of interleukin 2

1 reference

12 December 2020

Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells

1 reference

12 December 2020

Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marro

1 reference

12 December 2020

Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1).

1 reference

12 December 2020

Effect of cyclosporine A and methylprednisolone on the graft-versus-leukemia effects across major histocompatibility barriers in mice following allogeneic bone marrow transplantation

1 reference

12 December 2020

Graft-versus-leukemia reactions in clinical bone marrow transplantation

1 reference

12 December 2020

Quantitative measurement of human interleukin 2 receptor levels with intact and detergent-solubilized human T-cells

1 reference

12 December 2020

A phase II study of recombinant interleukin-2 with or without recombinant interferon-beta in non-Hodgkin's lymphoma. A study of the Cancer and Leukemia Group B

1 reference

12 December 2020

High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse

1 reference

12 December 2020

Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo

1 reference

12 December 2020

The effects of recombinant interleukin 2-activated natural killer cells on autologous peripheral blood hematopoietic progenitors

1 reference

12 December 2020

Effector cells of graft-versus-host disease, host resistance, and the graft-versus-leukemia effect: summary of a workshop on bone marrow transplantation.

1 reference

12 December 2020

Interleukin-2 +/- lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies.

1 reference

12 December 2020

Clinical immunotherapy studies in the Surgery Branch of the U.S. National Cancer Institute: brief review

1 reference

12 December 2020

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation

1 reference

12 December 2020

The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?

1 reference

12 December 2020

1 reference

12 December 2020

Rapid reappearance of large granular lymphocytes (LGL) with concomitant reconstitution of natural killer (NK) activity after human bone marrow transplantation (BMT)

1 reference

12 December 2020

Low-dose natural interleukin-2 and recombinant interferon-gamma following autologous bone marrow grafts in pediatric patients with high-risk acute leukemia.

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

Expression of interleukin 2 receptors on activated human B cells

1 reference

12 December 2020

Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy

1 reference

12 December 2020

Allogeneic bone marrow transplantation for poor-prognosis non-Hodgkin's lymphoma

1 reference

12 December 2020

Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia

1 reference

12 December 2020

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

12 December 2020

Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies

1 reference

12 December 2020

New developments in bone marrow transplantation

1 reference

12 December 2020

Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: a pilot study

1 reference

12 December 2020

Direct demonstration of the identity of T cell growth factor binding protein and the Tac antigen

1 reference

12 December 2020

The role of immunotherapy in the treatment of acute myeloblastic leukemia: from allogeneic bone marrow transplantation to the application of interleukin 2.

1 reference

12 December 2020

Expression of Tac antigen on activated normal human B cells

1 reference

12 December 2020

Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients

1 reference

12 December 2020

Polyethylene glycolated interleukin-2 as maintenance therapy for acute myelogenous leukemia in second remission

1 reference

12 December 2020

Local cutaneous reaction induced by subcutaneous interleukin-2 and interferon alpha-2a immunotherapy following ABMT

1 reference

12 December 2020

Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies.

1 reference

12 December 2020

Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation

1 reference

12 December 2020

IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity

1 reference

12 December 2020

1 reference

12 December 2020

Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-alpha 2a and interleukin-2.

1 reference

12 December 2020

T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse

1 reference

12 December 2020

Recombinant interleukin-2 and interferon alpha immunotherapy following autologous bone marrow transplantation. A case report of cardiovascular toxicity with serial echocardiographic evaluation

1 reference

12 December 2020

Graft-versus-leukemia reactions after bone marrow transplantation

1 reference

12 December 2020

A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer

1 reference

12 December 2020

Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues

1 reference

12 December 2020

Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2

1 reference

12 December 2020

Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia

1 reference

12 December 2020

Effect of various cytokine combinations on induction of non-MHC-restricted cytotoxicity

1 reference

12 December 2020

Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01571195

1 reference

Dimensions Publication ID

27 September 2017

1030982579

0 references

1 reference